Home › Funds › Holocene Advisors, LP › ABT
Holocene Advisors, LP position in ABT
ABBOTT LABORATORIES · Health Care
Holocene Advisors, LP reported holding 2,490,670 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$226.0M, representing 0.54% of its reported portfolio and ranking #44 among its reported holdings. Holocene Advisors, LP has disclosed ABT holdings in 6 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Holocene Advisors, LP's ABT position evolved
Holocene Advisors, LP first disclosed a stake in ABT in Q2 2024 at 407,635 shares (US$42.4M). The position peaked in Q2 2026 at 2,490,670 shares, worth US$226.0M. Across 6 filings, Holocene Advisors, LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,490,670 shares valued at US$226.0M — an increase of 1,699,754 shares quarter over quarter.. Notable position changes include a 112% increase in Q3 2024 (shares were roughly flat over the following quarter), a 54% trim in Q4 2024 (shares rose 18% over the following quarter), a 215% increase in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 407.63K | $42.36M | New |
| Q3 2024 | 862.27K | $98.31M | Add |
| Q4 2024 | 396.70K | $44.87M | Reduce |
| Q4 2025 | 843.40K | $105.67M | New |
| Q1 2026 | 790.92K | $81.20M | Reduce |
| Q2 2026 | 2.49M | $226.00M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Holocene Advisors, LP
FAQ
How long has Holocene Advisors, LP held ABT?
Holocene Advisors, LP has disclosed ABT holdings in 6 of the last 9 reported quarters, going back to Q2 2024.
What is Holocene Advisors, LP's current position in ABT?
As of Q2 2026, Holocene Advisors, LP holds 2.49M shares of ABT (ABBOTT LABORATORIES), valued at $226.00M, representing 0.54% of its reported portfolio and ranking #44.
Has Holocene Advisors, LP been buying or selling ABT?
In the latest 13F filing (Q2 2026), Holocene Advisors, LP increased its position in ABT. The position peaked in Q2 2026 at 2.49M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.